Matches in Wikidata for { <http://www.wikidata.org/entity/Q80791117> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q80791117 description "article scientifique publié en 2007" @default.
- Q80791117 description "artículu científicu espublizáu n'avientu de 2007" @default.
- Q80791117 description "bài báo khoa học" @default.
- Q80791117 description "im Dezember 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80791117 description "scientific article published on 01 December 2007" @default.
- Q80791117 description "wetenschappelijk artikel" @default.
- Q80791117 description "наукова стаття, опублікована в грудні 2007" @default.
- Q80791117 name "Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)" @default.
- Q80791117 name "Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)" @default.
- Q80791117 type Item @default.
- Q80791117 label "Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)" @default.
- Q80791117 label "Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)" @default.
- Q80791117 prefLabel "Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)" @default.
- Q80791117 prefLabel "Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)" @default.
- Q80791117 P1433 Q80791117-84A44124-89B0-4EB5-AD84-135322EF4A36 @default.
- Q80791117 P1476 Q80791117-5C3280F5-17E9-4360-B66D-10CEF8E7B0AA @default.
- Q80791117 P2093 Q80791117-25F8896E-715C-4551-A75E-58D35754775C @default.
- Q80791117 P2093 Q80791117-2B43A285-2379-4935-AE66-6ADB958E7697 @default.
- Q80791117 P2093 Q80791117-4330D1AF-1F1D-4DE2-B6A9-40EAA0C8A498 @default.
- Q80791117 P2093 Q80791117-6A087583-74BC-4660-8856-7752E1FD6EEC @default.
- Q80791117 P2093 Q80791117-8159CE5C-87EB-423B-8E36-5EDD6286A3BB @default.
- Q80791117 P2093 Q80791117-947B4B78-0917-4EE0-9295-69782D1BAB72 @default.
- Q80791117 P2093 Q80791117-BAE5AAFE-D8FC-4160-ACD9-B9A5311D17CA @default.
- Q80791117 P304 Q80791117-6F98E37E-8D66-4D76-BFBA-BC7C10B23091 @default.
- Q80791117 P31 Q80791117-191A058A-9117-4BA9-995E-46100FB8BD23 @default.
- Q80791117 P356 Q80791117-D1CD53B6-FC1E-42AB-81BB-DE322239EDE1 @default.
- Q80791117 P433 Q80791117-04FB5EE0-A302-48F9-88DE-5FF84EA5D37E @default.
- Q80791117 P478 Q80791117-18EB2471-A796-4407-8F9C-09E30B709627 @default.
- Q80791117 P50 Q80791117-8B28F70F-6BD8-4BD4-BC28-207BCFA17682 @default.
- Q80791117 P50 Q80791117-9A539F37-69BB-4142-8F58-DE34BF7FAB4C @default.
- Q80791117 P577 Q80791117-E391AF1C-D1BD-41D6-8684-7914F562FC9D @default.
- Q80791117 P698 Q80791117-D765F9E3-0D30-4C82-AE17-707010FED1DF @default.
- Q80791117 P921 Q80791117-1D8C3788-3E03-4875-AC99-6D746316A631 @default.
- Q80791117 P921 Q80791117-1F6C512D-9ADC-4A7D-AE28-E3F1083FF7ED @default.
- Q80791117 P921 Q80791117-FA03D196-AF7F-49E8-B362-E189007995CE @default.
- Q80791117 P356 AJH.20994 @default.
- Q80791117 P698 17696203 @default.
- Q80791117 P1433 Q4744246 @default.
- Q80791117 P1476 "Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)" @default.
- Q80791117 P2093 "Anand B Karnad" @default.
- Q80791117 P2093 "Cathryn Rankin" @default.
- Q80791117 P2093 "David R Head" @default.
- Q80791117 P2093 "Howard R Terebelo" @default.
- Q80791117 P2093 "Shaker R Dakhil" @default.
- Q80791117 P2093 "Stanley P Balcerzak" @default.
- Q80791117 P2093 "Stephen H Petersdorf" @default.
- Q80791117 P304 "1056-1062" @default.
- Q80791117 P31 Q13442814 @default.
- Q80791117 P356 "10.1002/AJH.20994" @default.
- Q80791117 P433 "12" @default.
- Q80791117 P478 "82" @default.
- Q80791117 P50 Q110811050 @default.
- Q80791117 P50 Q75025725 @default.
- Q80791117 P577 "2007-12-01T00:00:00Z" @default.
- Q80791117 P698 "17696203" @default.
- Q80791117 P921 Q180983 @default.
- Q80791117 P921 Q264118 @default.
- Q80791117 P921 Q411659 @default.